- Home
- HWH vs XAIR Comparison
HWH vs XAIR Comparison
Compare HWH & XAIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HWH | XAIR |
|---|---|---|
| Founded | 2021 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Pharmaceuticals | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.0M | 11.4M |
| IPO Year | 2022 | 2015 |
Fundamental Metrics
Financial Performance| Metric | HWH | XAIR |
|---|---|---|
| Price | $1.50 | $0.98 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $11.00 |
| AVG Volume (30 Days) | 19.2K | ★ 308.7K |
| Earning Date | 01-01-0001 | 05-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 62.09 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $3,705,000.00 |
| Revenue This Year | N/A | $126.42 |
| Revenue Next Year | N/A | $130.48 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 219.67 |
| 52 Week Low | $0.90 | $0.15 |
| 52 Week High | $7.77 | $3.78 |
Technical Indicators
Market Signals| Indicator | HWH | XAIR |
|---|---|---|
| Relative Strength Index (RSI) | 42.88 | 41.54 |
| Support Level | $1.33 | $0.98 |
| Resistance Level | $1.52 | $1.25 |
| Average True Range (ATR) | 0.12 | 0.10 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 40.00 | 19.60 |
Price Performance
Historical ComparisonAbout HWH HWH International Inc.
HWH International Inc is and its consolidated subsidiaries operate a food and beverage business in Singapore and South Korea. The F&B business operates four cafes, two of which are located in South Korea and two in Singapore, as well as an online healthy food store, serving customers in Singapore.
About XAIR Beyond Air Inc.
Beyond Air Inc is a commercial-stage medical device and biopharmaceutical company that develops a Nitric Oxide (NO) Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases. The firm is applying its therapeutic expertise to develop treatments for pulmonary hypertension, in addition to treatments for lower respiratory tract infections.